Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for ...

In a Phase 1/2 clinical trial, Moderna’s combination vaccine appeared to elicit “strong” immune responses against both influenza and Covid-19 and was found to be safe, the company announced ...

Moderna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune response in late-stage study results than two comparable vaccines on the market.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines. The shot’s efficacy was 27% higher ...

The mercury-based preservative thimerosal will be removed from all flu shots distributed in United States, Health and Human ...

Moderna tested a vaccine that combined its mRNA-based flu shot, mRNA-1010, with its Covid vaccine, mRNA-1283, in adults over 50 years old. For the flu, the combination vaccine generated a similar ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna has begun testing an mRNA flu vaccine in clinical trials, with the company announcing Wednesday that the first participants had been dosed in the Phase 1/2 study.